Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in Attention-Deficit/Hyperactivity Disorder

Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in Attention-Deficit/Hyperactivity Disorder

Background: Methylphenidate is among the most prescribed medications for treating attention-deficit/hyperactivity disorder (ADHD). However, nearly half of pediatric patients with ADHD do not respond to methylphenidate treatment. Pharmacogenetic testing can aid in identifying patients for whom methyl...

Full description

Bibliographic Details
Main Authors: Daniel T. Hain, Talal Al Habbab, Elizabeth S. Cogan, Holly L. Johnson, Rebecca A. Law, David J. Lewis
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:Biological Psychiatry Global Open Science
Subjects:
ADHD
ADRA2A
Meta-analysis
Methylphenidate
Pharmacogenetics
Stimulants
Online Access:http://www.sciencedirect.com/science/article/pii/S2667174321000860

Internet

http://www.sciencedirect.com/science/article/pii/S2667174321000860

Similar Items